Lowinger Timothy B

SVP, Chief Sci.&Tech. OfficerMersana Therapeutics, Inc. (MRSN) · full profile →Form 4 · filed Jan 6, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
22
1 non-derivative · 21 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 6, 2026Tender(U)10K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 6, 2026Disposed to issuer(D)8K0
Jan 6, 2026Disposed to issuer(D)2K0
Jan 6, 2026Disposed to issuer(D)2K0
Jan 6, 2026Disposed to issuer(D)2K0
Jan 6, 2026Disposed to issuer(D)3K0
Jan 6, 2026Disposed to issuer(D)7K0
Jan 6, 2026Disposed to issuer(D)6960
Jan 6, 2026Disposed to issuer(D)2K0
Jan 6, 2026Disposed to issuer(D)7130
Jan 6, 2026Disposed to issuer(D)4190
Jan 6, 2026Disposed to issuer(D)9200
Jan 6, 2026Disposed to issuer(D)3K0
Jan 6, 2026Disposed to issuer(D)2750
Jan 6, 2026Disposed to issuer(D)5K0
Jan 6, 2026Disposed to issuer(D)2150
Jan 6, 2026Disposed to issuer(D)3K0
Jan 6, 2026Disposed to issuer(D)8580
Jan 6, 2026Disposed to issuer(D)6K0
Jan 6, 2026Disposed to issuer(D)1K0
Jan 6, 2026Disposed to issuer(D)1920
Jan 6, 2026Disposed to issuer(D)7500

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-001371) within minutes of acceptance. Every field above traces to the original document. Verify it directly: